Steinsbekk Aslak, Bentzen Niels, Fønnebø Vinjar, Lewith George
Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Br J Clin Pharmacol. 2005 Apr;59(4):447-55. doi: 10.1111/j.1365-2125.2005.02336.x.
Homeopathic medicines are frequently purchased over the counter (OTC). Respiratory complaints are the most frequent reason for such purchases. Children with upper respiratory tract infection (URTI) are frequent users of homeopathy. This study investigates the effect of self treatment with one of three self selected ultramolecular homeopathic medicines for the prevention of childhood URTI.
A double-blind randomized parallel group placebo controlled trial was carried out in 251 children below the age of 10 years, recruited by post from those previously diagnosed with URTI when attending a casualty department. The children were randomly assigned to receive either placebo or ultramolecular homeopathic medicines in C-30 potency (diluted 10(-60)) administered twice weekly for 12 weeks. Parents chose the medicine based on simplified constitutional indications for the three medicines most frequently prescribed by Norwegian homeopaths for this group of patients. The main outcome measure relates to the prevention of new episodes of URTI measured with median total symptom score over 12 weeks.
There was no difference in the predefined primary outcome between the two groups (P = 0.733). Median URTI scores over 12 weeks in the homeopathic medicine group were 26.0 (95% confidence interval (CI) 16.3, 43.7) and for placebo 25.0 (95% CI 14.2, 38.4). There was no statistical difference between the two groups in median number of days with URTI symptoms or in the use of conventional medication/care.
In this study there was no effect over placebo for self treatment with one of three self selected, ultramolecular homeopathic medicines in preventing childhood URTI. This can be due to the lack of effect of the highly diluted homeopathic medicines or the process of selection and type of medicines.
顺势疗法药物经常在柜台购买。呼吸道疾病是购买此类药物的最常见原因。患有上呼吸道感染(URTI)的儿童是顺势疗法的频繁使用者。本研究调查了三种自行选择的超分子顺势疗法药物之一进行自我治疗对预防儿童URTI的效果。
对251名10岁以下儿童进行了一项双盲随机平行组安慰剂对照试验,这些儿童是通过邮寄从之前在急诊科就诊时被诊断为URTI的儿童中招募的。儿童被随机分配接受安慰剂或C-30效力(稀释10(-60))的超分子顺势疗法药物,每周服用两次,共12周。家长根据挪威顺势疗法医生针对该组患者最常开的三种药物的简化体质指标选择药物。主要结局指标涉及通过12周内的总症状评分中位数来衡量的预防URTI新发作情况。
两组之间预先定义的主要结局没有差异(P = 0.733)。顺势疗法药物组12周内URTI评分中位数为26.0(95%置信区间(CI)16.3,43.7),安慰剂组为25.0(95%CI 14.2,38.4)。两组在URTI症状天数中位数或使用传统药物/护理方面没有统计学差异。
在本研究中,三种自行选择的超分子顺势疗法药物之一进行自我治疗在预防儿童URTI方面对安慰剂没有效果。这可能是由于高度稀释的顺势疗法药物缺乏效果,或者是药物的选择过程和类型所致。